Pleiotropic effects of angiotensin-converting enzyme inhibitors in normotensive patients with coronary artery disease

Pharmacological Reports

Volumn 60, Issue 4, 2008, Pages 514-523

  Krysiak, Robert ^a   Okopień, Bogusław ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

Angiotensin converting enzyme inhibitors; Coronary artery disease; Cytokines; Hemostasis; Risk factors

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; FIBRINOGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 10; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MONOCYTE CHEMOTACTIC PROTEIN 1; OXIDIZED LOW DENSITY LIPOPROTEIN; PERINDOPRIL; PLACEBO; PLASMINOGEN ACTIVATOR INHIBITOR 1; TRIACYLGLYCEROL;

ADULT; AGED; ANTIOXIDANT ACTIVITY; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; COUGHING; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FIBRINOLYSIS; GLUCOSE BLOOD LEVEL; HEMOSTASIS; HUMAN; HYPOTENSION; INFLAMMATION; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; PATIENT COMPLIANCE; PLEIOTROPY; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SECONDARY PREVENTION; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 52049119316     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Braunwald E, Domanski MJ, Fowler SE, Geller NL, Gersh BJ, Hsia J, Pfeffer MA et al.: PEACE Trial Investigators: Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med, 2004, 351, 2058-2068.
2. Campbell DJ: A review of perindopril in the reduction of cardiovascular events. Vasc Health Risk Manag, 2006, 2, 117-124.
3. Constantinescu CS, Goodman DB, Ventura ES: Captopril and lisinopril suppress production of interleukin-12 by human peripheral blood mononuclear cells. Immunol Lett, 1998, 62, 25-31.
4. Dagenais GR, Pogue J, Fox K, Simoons ML, Yusuf S: Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials. Lancet, 2006, 368, 581-558.
5. Dendorfer A, Dominiak P, Schunkert H: ACE inhibitors and angiotensin II receptor antagonists. Handb Exp Pharmacol, 2005, 170, 407-442.
6. Di Napoli M, Papa F: Angiotensin-converting enzyme inhibitor use is associated with reduced plasma concentration of C-reactive protein in patients with first-ever ischemic stroke. Stroke, 2003, 34, 2922-2929.
7. Dzau VJ, Bernstein K, Celermajer D, Cohen J, Dahlöf B, Deanfield J, Diez J et al.: Pathophysiologic and therapeutic importance of tissue ACE: a consensus report. Cardiovasc Drugs Ther, 2002, 16, 149-160.
8. Fox KM; EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators: efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet, 2003, 362, 782-788.
9. Fukuzawa M, Satoh J, Sagara M, Muto G, Muto Y, Nishimura S, Miyaguchi S et al.: Angiotensin converting enzyme inhibitors suppress production of tumor necrosis factor-alpha in vitro and in vivo. Immunopharmacology, 1997, 36, 49-55.
10. Garanty-Bogacka B, Syrenicz M, Syrenicz A, Gebala A, Lulka D, Walczak M: Serum markers of inflammation and endothelial activation in children with obesity-related hypertension. Neuro Endocrinol Lett, 2005, 26, 242-246.
11. Holvoet P: Oxidized LDL and coronary heart disease. Acta Cardiol, 2004, 59, 479-484.
12. Jilma B, Li-Saw-Hee FL, Wagner OF, Beevers DG, Lip GY: Effects of enalapril and losartan on circulating adhesion molecules and monocyte chemotactic protein-1. Clin Sci, 2002, 103, 131-136.
13. Kothari SA, Le MK, Gandhi PJ: Effects of angiotensin converting enzyme inhibitors on thrombotic mediators: potential clinical implications. J Thromb Thrombolysis, 2003, 15, 217-225.
14. Krysiak R, Okopień B, Herman ZS: Effects of HMG-CoA reductase inhibitors on coagulation and fibrinolysis processes. Drugs, 2003, 63, 1821-1854.
15. Madej A, Okopień B, Kowalski J, Haberka M, Herman ZS: Plasma concentrations of adhesion molecules and chemokines in patients with essential hypertension. Pharmacol Rep, 2005, 57, 878-881.
16. Makris TK, Tsoukala C, Krespi P, Hatzincharias A, Gialeraki A, Papargyriou J, Votteas V et al.: Haemostasis balance disorders in patients with essential hypertension. Thromb Res, 1997, 88, 99-107.
17. Mitrovic V, Klein HH, Krekel N, Kreuzer J, Fichtlscherer S, Schirmer A, Paar WD et al.: Influence of the angiotensin converting enzyme inhibitor ramipril on high-sensitivity C-reactive protein (hs-CRP) in patients with documented atherosclerosis. Z Kardiol, 2005, 94, 336-342.
18. Moser L, Callahan KS, Cheung AK, Stoddard GJ, Munger MA: ACE inhibitor effects on platelet function in stages I-II hypertension. J Cardiovasc Pharmacol, 1997, 30, 461-467.
19. Naftilan AJ: Role of the tissue renin-angiotensin system in vascular remodeling and smooth muscle cell growth. Curr Opin Nephrol Hypertens, 1994, 3, 218-227.
20. Napoleone E, Di Santo A, Camera M, Tremoli E, Lorenzet R: Angiotensin-converting enzyme inhibitors downregulate tissue factor synthesis in monocytes. Circ Res, 2000, 86, 139-143.
21. Neultel JM: Effect of the renin-angiotensin system on the vessel wall: using ACE inhibition to improve endothelial function. J Hum Hypertens, 2004, 18, 599-606.
22. Okopień B, Kowalski J, Krysiak R, Łabuzek K, Stachura-Kułach A, Kułach A, Zieliński et al.: Monocyte suppressing action of fenofibrate. Pharmacol Rep, 2005, 57, 367-372.
23. Okopień B, Krysiak R, Herman ZS: Effects of short-term fenofibrate treatment on circulating markers of inflammation and hemostasis in patients with impaired glucose tolerance. J Clin Endocrinol Metab, 2006, 91, 1770-1778.
24. Paffen E, Vos HL, Bertina, RM: C-reactive protein does not directly induce tissue factor in human monocytes. Arterioscler Thromb Vasc Biol, 2004, 24, 975-981.
25. Peeters AC, Netea MG, Kullberg BJ, Thien T, van der Meer JW: The effect of renin-angiotensin system inhibitors on pro- and anti-inflammatory cytokine production. Immunology, 1998, 94, 376-379.
26. Piepho RW: Overview of the angiotensin-converting-enzyme inhibitors. Am J Health Syst Pharm, 2000, 57, Suppl 1, S3-S7.
27. PROGRESS Collaborative Group: Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet, 2001, 358, 1033-1041.
28. Schieffer B, Bunte C, Witte J, Hoeper K, Boger RH, Schwedhelm E, Drexler H: Comparative effects of AT1-antagonism and angiotensin-converting enzyme inhibition on markers of inflammation and platelet aggregation in patients with coronary artery disease. J Am Coll Cardiol, 2004, 44, 362-368.
29. Schindler R, Dinarello CA, Koch KM: Angiotensin-convetting-enzyme inhibitors suppress synthesis of tumour necrosis factor and interleukin 1 by human peripheral blood mononuclear cells. Cytokine, 1995, 7, 526-533.
30. Schmeisser A, Soehnlein O, Illmer T, Lorenz HM, Eskafi S, Roerick O, Gabler C et al.: ACE inhibition lowers angiotensin II-induced chemokine expression by reduction of NF-κB activity and AT1 receptor expression. Biochem Biophys Res Commun, 2004, 325, 532-540.
31. Sheth T, Parker T, Block A, Hall C, Adam A, Pfeffer MA, Stewart DJ et al.; IMPRESS Investigators: Comparison of the effects of omapatrilat and lisinopril on circulating neurohormones and cytokines in patients with chronic heart failure. Am J Cardiol, 2002, 90, 496-500.
32. Singh SK, Suresh MV, Voleti B, Agrawal A: The connection between C-reactive protein and atherosclerosis. Ann Med, 2008, 40, 110-120.
33. Singh U, Devaraj S, Dasu MR, Ciobanu D, Reusch J, Jialal I: C-reactive protein decreases interleukin-10 secretion in activated human monocyte-derived macrophages via inhibition of cyclic AMP production. Arterioscler Thromb Vasc Biol, 2006, 26, 2469-2475.
34. Sironi L, Nobili E, Gianella A, Gelosa P, Tremoli E: Anti-inflammatory properties of drugs acting on the renin-angiotensin system. Drugs Today, 2005, 41, 609-622.
35. Song JC, White CM: Do HMG-CoA reductase inhibitors affect fibrinogen? Ann Pharmacother, 2001, 35, 236-241.
36. Tikiz C, Utuk O, Pirildar T, Bayturan O, Bayindir P, Taneli F, Tikiz H et al.: Effects of angiotensin-converting enzyme inhibition and statin treatment on inflammatory markers and endothelial functions in patients with long-term rheumatoid arthritis. J Rheumatol, 2005, 32, 2095-2101.
37. Trevelyan J, Brull DJ, Needham EW, Montgomery HE, Morris A, Mattu RK: Effect of enalapril and losartan on cytokines in patients with stable angina pectoris awaiting coronary artery bypass grafting and their interaction with polymorphisms in the interleukin-6 gene. Am J Cardiol, 2004, 94, 564-569.
38. Tsikouris JP, Suarez JA, Meyerrose GE: Plasminogen activator inhibitor-1: physiological role, regulation, and the influence of common pharmacologic agents. J Clin Pharmacol, 2002 42, 1187-1192.
39. Wojewódzka-Zeleźakowicz M, Chabielska E, Mogielnicki A, Kramkowski K, Karp A, Opadczuk A, Domaniewski T et al.: Antithrombotic effect of tissue and plasma type angiotensin converting enzyme inhibitors in experimental thrombosis in rats. J Physiol Pharmacol, 2006, 57, 231-245.
40. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G: Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med, 2000, 342, 145-153.